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Clinical features and management of
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Aspectos clínicos e manejo das paraplegias espásticas hereditárias
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ABSTRACT
Hereditary spastic paraplegia (HSP) is a group of genetically-determined disorders characterized by progressive spasticity and weakness
of lower limbs. An apparently sporadic case of adult-onset spastic paraplegia is a frequent clinical problem and a significant proportion of
cases are likely to be of genetic origin. HSP is clinically divided into pure and complicated forms. The later present with a wide range of
additional neurological and systemic features. To date, there are up to 60 genetic subtypes described. All modes of monogenic inheritance
have been described: autosomal dominant, autosomal recessive, X-linked and mitochondrial traits. Recent advances point to abnormal
axonal transport as a key mechanism leading to the degeneration of the long motor neuron axons in the central nervous system in HSP. In
this review we aim to address recent advances in the field, placing emphasis on key diagnostic features that will help practicing
neurologists to identify and manage these conditions.
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RESUMO
Paraplegias espásticas hereditárias (PEH) constituem um grupo de desordens geneticamente determinadas caracterizadas por
espasticidade e paraparesia de progressão insidiosa. Paraplegia espástica aparentemente esporádica de início no adulto constitui
problema frequente na prática neurológica. Evidências recentes sugerem que uma proporção significativa destes casos é geneticamente
determinada. O grupo das PEH é dividido clinicamente em formas puras e complicadas de acordo com a concomitância de outras
manifestações clinicas e neurológicas. Até o momento 60 tipos genéticos foram identificados. Todos os modos de herança monogênica já
foram descritos: autossômica dominante, autossômica recessiva, ligada ao X e mitocondrial. Avanços recentes indicam que alterações
do transporte axonal estão implicadas na degeneração dos longos axônios motores no sistema nervoso central na PEH. Nesta revisão
abordamos recentes avanços na área com ênfase nos aspectos clínicos chave que ajudam o neurologista geral no diagnóstico e manejo
correto deste grupo de doenças.
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Hereditary spastic paraplegia (HSP) is a diverse group of
single-gene disorders characterized by retrograde degenera-
tion of the long axonal fibers of the corticospinal tracts and
posterior columns of the spinal cord. The key clinical feature
is slowly progressive pyramidal pattern of weakness1.
There are few epidemiological studies in HSP, but preval-
ence is estimated to range between 1.3 to 9.6 cases per
100,000 people2. In addition to clearly familial cases, a sig-
nificant proportion of patients with sporadic spastic paraple-
gia also have a genetic etiology. HSP represents a large
proportion of subjects attending specialized Movement
Disorders, Neuromuscular and Neurogenetics outpatient
clinics. Although traditionally regarded as a rare disorder,
HSP is almost as common as other disorders well known
by the general neurologist, such as: hereditary cerebellar
ataxias (prevalence rate of up to 8.9 people out of
100,000)3, motor neuron disease (6.3 per 100,000)4,5 and mul-
tiple system atrophy (4-5 per 100,000 people)6.
In recent years, several genes and loci associated to HSP
have been mapped1,7. On clinical grounds, these findings
helped neurologists to perform more accurate and earlier
diagnoses, as well as a sounder genetic counseling.
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Furthermore, key molecular pathways leading to neurode-
generation were unraveled, which might have short term
implications for novel therapies and result in a better under-
standing of closely related disorders, such as motor neuron
diseases and spinocerebellar ataxias.
In the present article, we review the core clinical features
of HSP, as well as the available therapeutic strategies. Our
ultimate objective is to help practicing neurologists to recog-
nize and to properly manage patients with HSP.
CLASSIFICATION
HSPs are a group of heterogeneous monogenic diseases.
They may segregate as an autosomal dominant, an autoso-
mal recessive, X-linked or mitochondrial trait1. To date, there
are up to 60 genetic types described7. Clinically, they are clas-
sified as pure or complicated forms. The later are associated
with a variety of other neurological and systemic abnormal-
ities, whereas the former essentially present with lower
limb weakness and spasticity. Most cases of pure HSP are
autosomal dominant, while complicated forms are inherited
mostly as autosomal recessive conditions. X-linked forms
may present either as pure or complicated HSP. This distinc-
tion is clinically useful, but is not always found in genotype-
phenotype correlation studies1.
AUTOSOMAL DOMINANT- HEREDITARY SPASTIC
PARAPLEGIA (AD-HSP)
AD-HSP represents 70% to 80% of HSPs. Almost half of
those are caused by mutations in the SPG4 gene that
encodes for the protein spastin8. SPG4 is also responsible
for approximately 10% of sporadic cases. In Brazil, we have
recently found that SPG4-related HSP accounts for 35% of
AD cases9. It shows a wide inter and intra-familial variability
in age of onset and disease severity suggesting the existence
of modifying factors10. It classically presents as a pure spastic
paraplegia. Recent studies though highlighted a frequent
association with cognitive decline, hand tremor and other
complicating features11,12.
Table 1. Current genetic classification of autosomal dominant hereditary spastic paraplegia.
Disease Gene symbol locus Protein Key clinical features
SPG3A SPG3A
14q22.1
Atlastin Pure early onset.
SPG4 SPAST
2p24-p21
Spastin pure HSP, highly variable onset. Late onset
cognitive impairment.
SPG6 NIPA1
15q11.2
NIPA1 (Not imprinted in
Prader-Willi/Angelman 1)
Pure, slowly progressive adult-onset.
SPG8 KIAA0196
8q24.13
Strumpellin Pure adult-onset.
SPG9 Gene unknown
10q23.3-q24.1
Unknown Complicated: Cataracts, motor neuropathy,
gastroesophageal reflux.
SPG10 KIF5A
12q13.13
Kinesin Family member 5A Pure or Complicated. Early-onset, distal amyotrophy.
SPG12 RTN2
19q13
Reticulon 2 Pure, early-onset.
SPG13 HSPD1
2q33.1
Heat shok 60KDa protein 1
(chaperonin) (M)
Pure, adult-onset.
SPG17 BSCL2
11q12-q13.5
Seipin Complicated: amyothrophy of hand muscles
(Silver-syndrome).
SPG19 Gene unknown
9q33-q34
Unknown Pure.
SPG29 1p31-p21 Unknown Complicated: deafness, persistent vomiting
from hiatal hernia.
SPG31 REEP1
2p11.2
Receptor expression
enhancing protein 1 (REEP1)
Pure. May be complicated by Silver-syndrome.
SPG33 ZFYVE27
10q24.2
Protrudin Pure.
SPG36 Gene unknown
12q23-q24
Unknown Early adulthood associated with polyneuropathy.
SPG37 Gene unknown
8p21.1-q13.3
Unknown Pure.
SPG38 Gene unknown
4p16-p15
Unknown Complicated: Silver-syndrome.
SPG41 Gene Unknown
11p14.1-p11.2
Unknown Pure or mild Silver-syndrome.
SPG42 SCL33A1
3q25.3
SCL33A1 (acetyl-CoA
transporter)
Pure, variable-onset incomplete penetrance.
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Mutations in the SPG3a gene, encoding for the protein
atlastin-1, are the second most common cause of AD-HSP
and the most common cause of early-onset disease13. Most
patients present with pure spastic paraplegia initiating
before the age of ten. SPG 31, related to mutations
in the REEP 1 gene, accounts for approximately 5% of
AD-HSP. It typically presents as early-onset spastic
paraplegia plus lower motor neuron disease, known as
Silver-syndrome14.
Mutations in the SPG 615 and SPG 816 are pure HSPs that
have already been identified in the Brazilian population. SPG
6 presents as a slowly progressive, mostly pure spastic para-
plegia in early-adulthood15 (Table 1).
AUTOSOMAL RECESSIVE- HEREDITARY SPASTIC
PARAPLEGIA (AR-HSP)
AR-HSP frequently present with pleomorphic associated
neurological and clinical abnormalities. While this adds
considerable challenges in the diagnostic workup, certain
specific complicating features may guide the differential
diagnosis between the different HSPs. As seen in other
recessive conditions, AR-HSP are more frequent in consan-
guineous populations.
Mutations in the gene SPG11, encoding spastacsin, are
the most frequent cause of AR-HSP, corresponding to up
to 20%17. This proportion increases to 60-80% when consid-
ering patients with thinning of the corpus callosum and
mental impairment18. Patients typically present around the
first or second decades with gait disturbances followed by
cognitive deterioration, peripheral neuropathy and move-
ment disorders, including dopa-responsive parkinsonism19.
Thinning of the corpus callosum is a hallmark of this con-
dition. In our center, SPG 11-HSP accounts for 45% of
patients with HSP and thinning of the corpus callosum20.
Atrophy of the corpus callosum is also a hallmark of
SPG15, associated with pigmental retinopathy and poly-
neuropathy21. Mutations in the SPG7 gene, which encodes
paraplegin, is the second most common cause of AR-HSP.
Its characteristic features include cerebellar ataxia, peri-
pheral neuropathy and optic atrophy22. SPOAN syndrome,
first described in Brazil is characterized by early and rapidly
progressive spastic paraplegia, optic atrophy and peripheral
neuropathy, but its gene is yet to be identified23 (Table 2).
X-LINKED
SPG1 gene encodes the protein NCAM24. Affected males
typically present with spastic paraplegia and hydrocephalus,
together with mental retardation, aphasia, shuffling gait and
adducted thumbs (MASA-syndrome).
SPG2 gene is also called proteolipoprotein or PLP1
gene25. The typical phenotype is composed of spastic para-
plegia associated with peripheral neuropathy and white mat-
ter abnormalities. Interestingly, duplications of this gene give
rise to the congenital hipomyelinating Pelizaeus-Merzbacher
disease25. SPG34 disease is a pure X-linked form of HSP
whose locus was first identified in Brazil, but its gene is
yet to be identified26,27 (Table 3).
MITOCHONDRIAL
A single family with five affected members has been
recently described with a mtDNA mutation in the ATP6 gene
clinically expressed as late onset spastic paraplegia28.
DIAGNOSIS
Diagnosis of HSP is based upon individual and family-
history as well as clinical and neurological findings such as
spastic weakness, hyperreflexia and extensor plantar
responses. These will guide further investigation to rule
out acquired causes of spastic paraplegia and orient specific
molecular diagnosis. The absence of family history should
not eliminate the diagnosis of HSP. At times, mildly affected
members or false paternity are not recognized, so a detailed
history and examination of apparently healthy family mem-
bers is desirable. HSP is characterized by normal motor
development followed by slowly progressive spasticity and
weakness of the lower limbs. The clinical spectrum and
the age of onset vary widely. Disproportionate spasticity in
contrast with mild weakness is a hallmark of this disorder.
Mild reduction of vibration sense, or other sensory abnor-
malities together with urinary symptoms are frequent even
in pure forms1. Complicated HSP comprise a large number
of abnormalities such as ataxia, peripheral neuropathy,
amyotrophy, seizures, movement disorders, cognitive impair-
ment, retinopathy, optic atrophy, deafness and others29,30.
An apparently sporadic case of slowly progressive spas-
ticity and weakness of the lower limbs is a fairly frequent
clinical problem in neurological practice. HSP is a diagnosis
of exclusion, especially in the absence of family history.
Spinal cord compression, infectious, inflammatory, meta-
bolic and ischemic myelopathies must be ruled out. We sug-
gest a basic workup composed of: serology for human T cell
leukemia virus, HIV and syphilis, as well as measurement of
serum copper, ceruloplasmin, ferritin, vitamin B12 and vit-
amin E levels. In selected cases, quantification of serum very
long chain fatty acids may be desirable to screen for adreno-
myeloneuropathy. Magnetic resonance of the cervical spine
is necessary to exclude spinal cord compression, inflammat-
ory or ischemic myelopathies. Brain MRI is desirable since it
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Table 2. Current genetic classification of autosomal recessive hereditary spastic paraplegia.
Disease Gene symbol locus Protein Key clinical features
SPG5 CYP7B1
8p12-q13
Cytochrome P450, family 7,
subfamily B, polypeptide 1
Pure or complicated: generalized muscle atrophy and white matter lesions.
SPG7 SPG7
16q24.3
Paraplegin Pure and complicate: amyotrophy, dysarthria, dysphasia, cerebellar
and optic atrophy.
SPG11 SPG11
15q14
Spatacsin Pure and complicated/early onset, cognitive impairment, neuropathy,
movement disorders, TCC.
SPG14 Gene Unknown
3q27-q28
Unknown Complicated: polineuropathy, mental retardation.
SPG15
(Kjellin)
ZFYVE26
14q24.1
Spastizin Complicated: spastic paraplegia with macular dystrophy, mental
retardation and amyotrophia (Kjellin syndrome).
SPG18 ERLIN2
p11.23
Erlin-2 Complicated: mental retardation, TCC.
SPG20
(Troyer)
SPG20
13q12.3
Spartin Complicated: dysarthria and distal amyotrophy.
SPG21
(Mast)
SPG21
15q21-q22
Maspardin Complicated: cognitive decline, movement disorders, TCC, white
matter abnormalities.
SPG23
(Lison)
Gene unknown
1q24-q32
Unknown Complicated/skin and hair pigmentary lesions, skeletal abnormalities.
SPG24 Gene unknown
13q14
Unknown Pure/spastic dysarthria and pseudobulbar signs
SPG25 Gene unknown
6q23.3-q24.1
Unknown Complicated: multiple disc herniation, cataract, congenital glaucoma.
SPG26 Gene unknown
12p11-q14
Unknown Child onset, complicated:distal amyotrophy cognitive impairment,
dysarthria.
SPG27 Gene unknown
10q22-q24
Unknown Pure or complicated: cognitive impairment, ataxia, dysarthria,
polyneuropathy, short stature, dismorphic face.
SPG28 DDHD1
14q22.1
DDHD1 Pure early-onset.
SPG29 Gene unknown
1p31.1-p21.1
Unknown Pure, childhood onset.
SPG30 KIF1A
2q37.3
Kinesin family member 1A Complicated: ataxia, sensory neuropathy.
SPG32 Gene unknown
14q12-q21
Unknown Complicated: mental retardation, ataxia, brainstem dysraphia and
cerebellar atrophy.
SPG35 FA2H
16q21-q23.1
Fatty acid 2-hydroxilase Childhood onset, complicated: cognitive decline, movement disorders,
epilepsy. Brain white matter lesions and iron accumulation.
SPG39 PNPLA6
19p13.2
Neuropathy Target Esterase
(NTE)
Complicated: childhood onset, marked distal wasting in all four limbs.
SPG43 Gene unknown
19p13.11-q12
Unknown Complicated: Silver-syndrome and dysarthria.
SPG44 CJC2
1q42.13
Connexin 47 Adulthood onset complicated: cognitive decline, spasticity of
four limbs.
SPG45 Gene unknown
10q24.3-q25.1
Unknown Childhood onset complicated: mental retardation, optic athrophy.
SPG46 Gene unknown
9p21.2-q21.12
Unknown Dementia, congenital cataract, ataxia, TCC.
SPG47 AP4B1
1p13.2
AP-4 complex subunit beta-1 Complicated: neonatal hypotonia, progressive hypertonia,
severe mental retardation, ataxia, seizures, TCC.
SPG48 KIAA0415
7p22.1
KIAA0415 Pure.
SPG49 TECPR2
14q32.31
Unknown Delayed psychomotor development, early spasticity, dismorphic
features, TCC, central apnea.
SPG50 AP4M1
7q22.1
Adaptor-related protein
complex 4, mu 1 subunit
Complicated/neonatal hypotonia that progresses to hypertonia.
Severe mental retardation.
SPG51 AP4E1
15q21.2
Adaptor-related protein
complex 5, zeta 1 subunit
Complicated: neonatal hypotonia that progresses to hypertonia.
Severe mental retardation. Same phenotype as SPG50.
SPG52 AP4S1
14q12
AP4S1 Complicated: neonatal hypotonia that progresses to hypertonia.
Dysmorphic features.
SPG53 Gene unknown
8p22
VSP37A Complicated: psychomotor delay, spasticity of four limbs.
SPG54 DDHD2
8p11
Unknown Psychomotor delay, cognitive impairment, dismorphic features. TCC
and white matter lesions.
SPG55 C12orf65
12q24.31
C12orf65 Early onset. Complicated: polyneuropathy and optic atrophy.
SPG56 CYP2U1
4q.25
CYP2U1 Early onset, spasticity of four limbs, polyneuropathy.
SPOAN Gene unknown
11q13
Gene unknown Early onset, spastic paraplegia, optic atrophy and axonal neuropathy.
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may show specific findings such as thinning of the corpus
callosum, white matter abnormalities and hydrocephalus,
which will help guide further molecular testing. Spinal fluid
analysis is warranted when history and previous tests did
not exclude inflammatory and infectious myelopathies.
In the clinical setting of AD-HSP, screening for mutations
in SPG4 is the first step, followed by SPG3a in negative
cases13,31. If spastic paraplegia initiated before the age of
ten, SPG3a gene should be analyzed first. SPG31 is the next
gene to be sequenced in negative cases32. Screening for these
three genes will likely identify mutations in more than 50%
of the patients.
Molecular investigation for AR-HSP should be guided by
the complicating features. SPG11 is the most prevalent form
of AR-HSP, its likelihood increases to up to 80% in the pres-
ence of cognitive decline and thinning of the corpus callo-
sum18. Currently in Brazil, patients must be referred to
research centers for HSP gene sequencing.
Due to its phenotypic variability, the differentiation
between various forms of HSP can be difficult on clinical
grounds. In selected cases, it is reasonable to consider other
neurodegenerative diseases on the differential diagnosis.
Motor neuron disease, spinocerebellar ataxias, and neurode-
generation with brain-iron accumulation are conditions that
may show clinical overlap with HSP33. Spinocerebellar ataxia
type 3, also named Machado-Joseph disease, is the most
common autosomal dominant spinocerebellar ataxia, and
has been previously highlighted as a differential diagnosis
for complicated HSP in Brazil34.
PATHOPHYSIOLOGY
HSPs are characterized by retrograde degeneration of the
longest neurons of the spinal cord, the corticospinal tract
and the posterior columns35. Due to their length and high
metabolic needs, these neurons are highly susceptible to
impaired transport of macromolecules and organelles. Des-
pite its genetic heterogeneity, disruptive processes involving
membrane trafficking and organelle morphogenesis and dis-
tribution seem to play a central role in the pathophysiology
of most HSPs29,30,36.
HSP-related proteins cluster into overlapping functional
classes: membrane trafficking, organelle shaping, mitochon-
drial regulation, lipid metabolism and axon path finding.
The three most common AD-HSPs (SPG4, SPG3A, SPG31)
are due to altered function of proteins involved in shaping
the endoplasmic reticulum, a function highly dependent
on microtubules37,38. Microtubule-targeting drugs have
shown positive results in animal models of SPG439.
NEUROIMAGING STUDIES
In cases of proven HSP the most common neuroimaging
finding is thinning of the spinal cord40. Although less fre-
quent, brain abnormalities are often found in HSPs and this
may be valuable to guide genotyping strategy. SPG11, the
most common cause of AR-HSP, must be suspected when
thinning of the corpus callosum is present, especially when
accompanied by the ears of the linx sign (Figures 1A and
B) and widespread white matter abnormalities41,42,43. A
recent study from our group showed that these patients also
have significant grey matter volume reduction in specific
cortical areas and the deep nuclei. These are the areas with
higher expression of spastacsin in the brain and this pattern
helps us to understand why movement disorders are so fre-
quent in SPG 1142. Despite this, one must consider that thin-
ning of the corpus callosum is not SPG11-specific, because it
is also found in other HSPs such as: SPG 4, 7, 15, 18, 21, 46,
47, 49 and 543,11,21,44,45,46. Progressive hydrocephalus due to
aqueductal stenosis is highly suggestive of X-linked SPG1.
White matter abnormalities may be found in some AR-
HSP, such as SPG 5, SPG 21, SPG 35 or autosomal recessive
spastic ataxia with leukoencephalopathy (ARSAL)47. In SPG2,
white matter abnormalities are also typical; they resemble
(but to a lesser extent) the diffuse hypomyelination found
in the allelic Pelizaeus-Merzbacher disease25,48 (Figure 2).
Table 3. Current genetic classification of X-linked hereditary spastic paraplegia.
Disease Gene locus Protein Key clinical features
SPG1
(MASA)
L1CAM
Xq28
L1 cell adhesion
molecule
Complicated: mental retardation, aphasia, shuffling gait, adducted thumbs.
Aqueductal stenosis wih hydrocephalus (MASA syndrome).
SPG2 PLP1
Xq22
Proteolipid protein 1 Pure or complicated: optic atrophy, ataxia, mental retardation,
white matter lesions.
SPG16 Gene unknown
Xq11.2
unknown Pure or complicated: aphasia, mental retardation, impaired vision.
SPG22 Xq13.2 Monocarboxylate
transport 8 (MCT8)
Complicated (Allan-Herndon-Dudley syndrome): congenital neck hypotonia,
psychomotor delay, early-spastcity, ataxia, dismorphic features.
SPG34 Gen unknown
Xq24-q25
unknown Pure. All families described in Brazil.
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FINAL REMARKS
Despite the lack of disease modifying therapies, adequate
prognostic counseling is of great importance for patients,
family members and healthcare professionals. Outcome of
patients with HSP is highly variable and specific molecular
diagnosis provides more accurate information. Diagnosis is
also warranted to prevent patients from been submitted
to unnecessary diagnostic tests. Patients with pure HSP mostly
have a normal life-spam. Wheelchair users, especially
when this milestone is reached early in life, are more suscept-
ible to secondary cardiovascular, pulmonary and infectious
complications. In complex cases, prognosis is strongly deter-
mined by additional manifestations. The course of the spastic
paraplegia itself is usually slowly progressive; in some patients
with extremely early onset, the disease may even resemble a
static condition such as diplegic cerebral palsy. Overall, disabil-
ity in patients with pure HSP tends to progress slower than in
patients with spinocerebellar ataxias49.
Spasticity is the most disabling feature in the majority of
cases. Treatment options include oral anti-spastic agents,
such as baclofen and tizanidine. If these drugs are ineffect-
ive, chemodenervation with botulinum toxins may be
attempted50,51. In our experience, the use of low doses of
botulinum toxin associated with proper physical therapy
( focused on stretching and strengthening) benefits the
patientás ambulatory capacity, provides pain relief and pre-
vents contractures and deformities. Signs and symptoms of
parkinsonism should be actively investigated since it can
be alleviated with dopaminergic drugs. Neuropathic pain is
managed with antidepressants (amytriptiline, nortryptiline,
duloxetin) or anticonvulsants (pregabalin, gapapentin).
Urinary urgency can be alleviated with anticholinergic drugs52.
As the disease progresses patients should be evaluated for
the appropriate assistive walking devices such as walkers and
wheelchairs. In case of prominent distal weakness affecting
foot dorsiflexion it is reasonable to use ankle-foot orthoses.
Secondary deformities such as scoliosis, tendon contractures
and foot deformities may require surgical management.
Figure 2. Magnetic resonance imaging of the brain of a patient
with mutation in the PLP1 gene (SPG2 phenotype). Axial T2
weighted images show widespread hyperintensity along
cerebral white matter. (Images from Professsor Maria Augusta
Montenegro, Departamento de Neurologia, Universidade
Estadual de Campinas).
Figure 1. Magnetic resonance imaging of the brain of a patient with mutation in the SPG11 gene (SPG11 phenotype): Sagittal
T1 weighted imaging showing thinning of the Corpus Callosum (A). Axial FLAIR imaging showing the "ears of the lynx" sign (red
arrows) (B).
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CONCLUSIONS
HSP is a group of disorders in which the long motor neu-
ron axons are predominantly affected, leading to slowly pro-
gressive pyramidal weakness of the lower limbs with relative
preservation of other body parts. Phenotypic and genotypic
heterogeneity contributes to under recognition of the dis-
ease. Increasing awareness about this disorder is especially
important for patients and researchers nowadays, since
there is rapid progression on the field. Detection of new cau-
sative genes, HSP-related proteins and its mechanisms may
bring treatment perspectives in the near future as well as
provide clues about other similar neurodegenerative dis-
eases of the motor system53.
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